Cardiff Oncology, Inc. (XE7C.F)

2.7150 -0.1250 (-4.40%) At close: 08:18AM CEST

Cardiff Oncology, Inc.

11055 Flintkote Avenue
San Diego, CA 92121
United States
858 952 7570
https://www.cardiffoncology.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 31

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mark Erlander Ph.D.	CEO & Director	803.94k	N/A	1960
Mr. James E. Levine	Chief Financial Officer	590.04k	N/A	1971
Dr. Fairooz Kabbinavar FACP, M.D.	Chief Medical Officer	602.86k	N/A	1957
Dr. Tod Smeal Ph.D.	Chief Scientific Officer?	2.47M	N/A	1965
Ms. Elizabeth Anderson	VP of Finance & Administration	N/A	N/A	N/A
Ms. Brigitte Lindsay	Senior Vice President of Finance	N/A	N/A	N/A
Mr. Charles Monahan R.Ph.	Senior VP of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Corporate governance

Cardiff Oncology, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.